Neuralink movement ambitions remain investigational, not established

By Marcus Bennett

Telepathy is in ongoing human clinical trials, while Blindsight holds only FDA Breakthrough Device Designation; Neuralink has not demonstrated natural hand or leg movement in humans. Musk says Blindsight awaits regulatory approval, and the company is preparing future trials.

What does Musk’s October 30 prediction change?

In an October 30 post on X, formerly Twitter, Musk said scientists could redirect signals from the brain’s motor and sensory regions to the limbs, potentially helping people with paralysis use their hands and walk again.

“Hopefully, in a few years, we will be able to shunt signals from the motor and sensory areas of the brain to the limbs and enable people to use their hands and walk again,” Musk wrote.

The proposed mechanism addresses the physiological break created by spinal cord injury. The brain normally sends electrical signals through the spinal cord and peripheral nerves to initiate walking, object pickup and finger movement; injury can interrupt those commands even when the brain still expresses the intention to move.

A limb-restoring brain-computer interface would need to capture movement intent, carry it through an intact route and convert it into limb action.

That final step remains unshown in the reported work. The account provides no participant count, signal fidelity, control latency, movement endpoints, safety outcomes or peer-reviewed efficacy analysis for hand or walking restoration. The October 30 statement therefore remains a forecast, not a trial result, while Neuralink’s ongoing trials continue to investigate implant safety and effectiveness.

What can Telepathy do today?

Telepathy, Neuralink’s first product, is the nearer clinical program. Its implant records neural activity associated with intended movement and converts that activity into digital commands. The intended use in severe paralysis includes moving a computer cursor, clicking items and performing digital tasks without physical hand movement.

Ongoing trials also explore robotic-arm control. Neuralink says participants have used the technology for gaming, writing code, creating digital art and communicating with family. Those reports indicate a range of user activities, but the account supplies no number of participants, task completion rates, error rates, latency or adverse-event figures, and it provides no comparison with other assistive-control systems.

Musk frames Telepathy more broadly, describing thought-based communication with computers and other people. He says its output bandwidth could eventually exceed the fastest human speech or typing; the long-term goal extends beyond cursor control to translating thought into words and actions at speeds potentially above both typing and spoken communication. No quantitative bandwidth result accompanies that claim.

What remains before Blindsight enters a trial?

Blindsight, Neuralink’s second device, targets severe visual impairment, including people who have been blind since birth, with the aim of providing some visual perception. A camera captures the surrounding scene, and the implant transmits visual information directly to the brain’s visual cortex, bypassing damaged eyes or optic nerves.

Musk says Blindsight is ready from an engineering standpoint and now waits for regulatory approval. Neuralink says the company is preparing future clinical trials.

The device holds FDA Breakthrough Device Designation, a status intended to accelerate development and review for technologies addressing serious medical conditions. The designation itself grants neither FDA approval nor clearance and does not make the device ready for widespread use.

For neurophysiology teams planning a trial, that distinction keeps the clinical questions separate. Telepathy concerns implanted decoding of movement intent into digital commands and experimental robotic-arm control; Blindsight proposes camera-derived visual information delivered to cortex. No Blindsight human cohort, implantation series, visual-acuity endpoint or safety dataset appears in the available information, so useful perception remains unestablished in a person.

Where does the movement claim stand?

Together, the two programs express Neuralink’s broader ambition to use brain-computer interfaces for communication, movement and interaction with the world. Musk’s longer-term goal would reconnect the brain with body parts that no longer respond to its signals, potentially giving people with paralysis greater independence. His central claim remains a research direction rather than a demonstrated treatment.

The immediate translational test for Telepathy extends beyond whether a cursor can move: decoded intent must support reliable, safe assistive control. Restoring natural hand or leg action requires a further step beyond digital or robotic output, including sensory feedback; the available information does not specify how that bidirectional pathway would work.

Reported cohort characteristics, implantation and follow-up intervals, decoding performance, control latency, adverse events and functional outcomes would provide the missing clinical basis. Musk’s prediction of walking again “in a few years” remains a future possibility rather than an established capability.